Evidence map›Paper›PMID 40744022›Full record

ArticleCell reports. Medicine2025

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity.

Julie J Ahn, Steven Dudics, David P Langan, Jeffrey D Smith, Alice H Hsu, Jacob C McCright, Sawyer R Smith, Alicia L Castleberry, Benjamin I George, Javier A Goitía Vázquez and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Julie J AhnDeka Biosciences, Inc., Germantown, MD, USA.
Steven DudicsDeka Biosciences, Inc., Germantown, MD, USA.
David P LanganDeka Biosciences, Inc., Germantown, MD, USA.
Jeffrey D SmithDeka Biosciences, Inc., Germantown, MD, USA.
Alice H HsuDeka Biosciences, Inc., Germantown, MD, USA.
Jacob C McCrightDeka Biosciences, Inc., Germantown, MD, USA.
Sawyer R SmithDeka Biosciences, Inc., Germantown, MD, USA.
Alicia L CastleberryDeka Biosciences, Inc., Germantown, MD, USA.
Benjamin I GeorgeDeka Biosciences, Inc., Germantown, MD, USA.
Javier A Goitía VázquezDeka Biosciences, Inc., Germantown, MD, USA.
Phillip N KuriDeka Biosciences, Inc., Germantown, MD, USA.
Sri Sai Vivek AllaDeka Biosciences, Inc., Germantown, MD, USA.
Jennifer GarciaDeka Biosciences, Inc., Germantown, MD, USA.
Young Min HaiderDeka Biosciences, Inc., Germantown, MD, USA.
Fatima W HamdanDeka Biosciences, Inc., Germantown, MD, USA.
Jhonnatan Esquivel JuárezDeka Biosciences, Inc., Germantown, MD, USA.
Robert ReddyDeka Biosciences, Inc., Germantown, MD, USA.
Aranganathan ShanmuganathanDeka Biosciences, Inc., Germantown, MD, USA.
Yuanyuan WangDeka Biosciences, Inc., Germantown, MD, USA.
Arielle WelchDeka Biosciences, Inc., Germantown, MD, USA.
David BoclairDeka Biosciences, Inc., Germantown, MD, USA.
Pavel A KhrimianDeka Biosciences, Inc., Germantown, MD, USA.
Christopher H YaenDeka Biosciences, Inc., Germantown, MD, USA.
John B MummDeka Biosciences, Inc., Germantown, MD, USA. Electronic address: mummj@dekabiosciences.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wild-type interleukin (IL)-2 induces anti-tumor immunity and toxicity, predominated by vascular leak syndrome (VLS) leading to edema, hypotension, organ toxicity, and regulatory T cell (Treg) expansion. Efforts to uncouple IL-2 toxicity from its potency have failed in the clinic. We hypothesize that IL-2 toxicity is driven by cytokine release syndrome (CRS) followed by VLS and that coupling IL-2 with IL-10 will ameliorate toxicity. Our data, generated using human primary cells, mouse models, and non-human primates, suggest that coupling of these cytokines prevents toxicity while retaining cytotoxic T cell activation and limiting Treg expansion. In syngeneic murine tumor models, DK2

Indexed as

Interleukin-10Interleukin-2NeoplasmsAnimalsCell Line, TumorCytokine Release SyndromeErbB ReceptorsFemaleHumansKiller Cells, NaturalMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryErbB ReceptorsInterleukin-10Interleukin-2cytokinecytokine release syndromeEGFRIFNγIL-10IL-2immunotherapytargeted therapyT cell exhaustionvascular leak syndrome

Identifiers

PMID40744022
PMCPMC12432382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.